FOR FURTHER INFORMATION CONTACT: Pauline C. Campbell, Response and Recovery Directorate, Federal Emergency Management Agency, Washington, DC 20472, (202) 646–3606.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the incident period for this disaster is closed effective October 21, 1996.

(Catalog of Federal Domestic Assistance No. 83.516, Disaster Assistance)

Lacy E. Suiter,

Executive Associate Director, Response and Recovery Directorate.

[FR Doc. 96–29897 Filed 11–21–96; 8:45 am]

BILLING CODE 6718–02–P

FEDERAL MARITIME COMMISSION

Notice of Agreement(s) Filed

The Commission hereby gives notice of the filing of the following agreement(s) under the Shipping Act of 1984.

Interested parties can review or obtain copies of agreements at the Washington, DC offices of the Commission, 800 North Capitol Street, N.W., Room 962. Interested parties may submit comments on an agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days of the date this notice appears in the Federal Register.

Agreement No: 202–011456–016.

Title: South Europe American Conference.

Parties:

DSR-Senator Lines GmbH
Evergreen Marine Corporation (Taiwan) Ltd.
Italia di Navigazione, S.p.A.
A.P. Moller-Maersk Line
Nedlloyd Lijnen B.V.
P & O Containers Limited
Sea-land Service, Inc.
Zim Israel Navigation Company, Ltd.

Synopsis: The proposed amendment would allow members to join only one loading range of the Eastbound Section of the conference. Other conforming language changes are also being made.

Agreement No: 217–011557.

Title: Contship/Zim/TMM Space Charter Agreement.

Parties:

Contship Containerlines Limited (''Contship'')
Transportacion Maritima Mexicana, S.A. de C.V. (''TMM'')
Zim-Israel Navigation Co., Ltd. (''Zim'')

Synopsis: The proposed Agreement would permit Zim to charter space from Contship and TMM aboard their vessels operated in the trade between United States Gulf Coast and Florida ports and ports in Italy, France, Spain, Portugal, and Mexico. The parties have requested a shortened review period.

Dated: November 18, 1996.

By order of the Federal Maritime Commission.

Joseph C. Polking,

Secretary.

[FR Doc. 96–29922 Filed 11–21–96; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Wednesday, November 27, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: November 20, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96–30005 Filed 11–20–96; 10:40 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Laboratory Evaluation of Whole Body Isometric Strength Capability During Simulated Scaffold End Frame Lifting.

Time and Date: 1 p.m.–3 p.m., December 13, 1996.

Place: Suncrest Facility, Large Conference Room, NIOSH, CDC, 3040 University Avenue, Morgantown, West Virginia 26505.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: Participants will provide NIOSH with their individual advice and comments regarding technical and scientific aspects of the NIOSH study ''Laboratory Evaluation of Whole Body Isometric Strength Capability during Simulated Scaffold End Frame Lifting.'' Peer review panelists will review the study protocol and provide individual advice on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited.

Agenda items are subject to change, as priorities dictate.

Contact Person for Additional Information: Robert G. Cutlip, Ph.D., M/S 119, 1095 Willowdale Road, Morgantown, West Virginia 26505, telephone 304/285–5968.

Dated: November 18, 1996.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–29872 Filed 11–21–96; 8:45 am]

BILLING CODE 4160–19–P

Food and Drug Administration

[Docket No. 96N–0402]

Agency Information Collection Activities: Proposed Collection

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995, Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information and to allow 60 days for public comment in response to the notice. The agency is also announcing that it intends to send blood banks, blood collection facilities, and blood component manufacturing facilities the annual request to complete Blood Establishment Registration and Product Listing, Form FDA 2830. This notice solicits comments on blood establishment registration and product listing requirements using form FDA 2830.

DATES: Submit written comments on the collection of information by January 21, 1997.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Geraldine M. Hogan, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1481.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. FDA submitted a copy of this notice to OMB for its review of this information collection, and requested emergency processing. OMB approved the information collection through February 28, 1997, and assigned OMB control number 0910–0052. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information listed below.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Blood Establishment Registration and Product Listing, Form FDA 2830—21 CFR Part 607—(OMB Control Number 0910–0052)

Under section 510 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360) any person owning or operating an establishment that manufactures, prepares, propagates, compounds, or processes a drug or device must register with the Secretary of Health and Human Services, on or before December 31 of each year, his or her name, place of business and all such establishments, and submit, among other information, a listing of all drug or device products manufactured, prepared, propagated, compounded, or processed by him or her for commercial distribution. In 21 CFR part 607, FDA has issued regulations implementing these requirements for manufacturers of human blood and blood products. Pursuant to these regulations, the agency seeks the information required by the act, including the location of the facility, name of the reporting official, type of ownership, type of establishment, and identification of blood and blood products being manufactured. Among other uses, this information assists FDA in its inspections of facilities, and its collection is essential to the overall regulatory scheme designed to ensure the safety of the nation's blood supply. Form FDA 2830, Blood Establishment Registration and Product Listing, is used to collect this information. The likely respondents are blood banks, blood collection facilities, and blood component manufacturing facilities.

FDA estimates the burden of this collection of information as follows: Based upon the past experience of the Center for Biologics Evaluation and Research, Division of Blood Applications, in regulatory blood establishment registration and product listing with new blood banks, the time needed for industry to complete the FDA 2830 is estimated to be 1 hour. For annual re-registration of blood banks, the time needed for industry to complete the FDA 2830 form is estimated to be ½ hour because re-registrants only need to refer to their files or written instructions for a small portion of the information required. Blood banks should familiar with the regulations and registration requirements to fill out this form.

ESTIMATED ANNUAL REPORTING BURDEN

Form No. FDA 2830 (21 CFR Part 607)	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Initial registration	300	1	300	1	300
Re-registration	3,000	1	3,000	0.5	1,500
Total	3,300		3,300		1,800

There are no capital costs or operating and maintenance costs associated with this collection.

Persons are not required to respond to a collection of information unless it displays a currently valid OMB control number.

Dated: November 15, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–29832 Filed 11–21–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0416]

Agency Information Collection Activities; Submission for OMB Review; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments on the collection of information by December 23, 1996.

ADDRESSES: Submit written comments on the collection of information to the